Influence of fluoxetine on olanzapine pharmacokinetics
Journal Title: The AAPS Journal - Year 2002, Vol 4, Issue 2
Abstract
Conventional antidepressant treatment fails for up to 30% of patients with major depression. When there are concomitant psychotic symptoms, response rates are even worse. Thus, subsequent treatment often includes combinations of antidepressants or augmentation with antipsychotic agents. Atypical antipsychotic agents such as olanzapine cause fewer extrapyramidal adverse effects than conventional antipsychotics; for that reason, they are an advantageous augmentation strategy for treatment-resistant and psychotic depression. The purpose of this study was to assess the potential for pharmacokinetic interaction between olanzapine and fluoxetine, a popular antidepressant that is a selective serotonin reuptake inhibitor. The pharmacokinetics of 3 identical single therapeutic doses of olanzapine (5 mg) were determined in 15 healthy nonsmoking volunteers. The first dose of olanzapine was taken alone, the second given after a single oral dose of fluoxetine (60 mg), and the third given after 8 days of treatment with fluoxetine 60 mg, qd. Olanzapine mean Cmax was slightly higher (by about 18%) and mean CL/F was slightly lower (by about 15%) when olanzapine was coadministered with fluoxetine in single or multiple doses. Olanzapine mean t1/2 and median tmax did not change. Although the pharmacokinetic effects of fluoxetine on olanzapine were statistically significant, the effects were small and are unlikely to modify olanzapines safety profile. The mechanism of influence is consistent with an inhibition of CYP2D6, which is known to control a minor pathway of olanzapine metabolism.
Authors and Affiliations
Denis Gossen, Jean-Marie de Suray, Francois Vandenhende, Claude Onkelinx, Diamon Gangji
Keywords
Related Articles
- EP ID EP682001
- DOI 10.1208/ps040209
- Views 120
- Downloads 0
Advancing Product Quality: a Summary of the Inaugural FDA/PQRI Conference
On September 16 and 17, 2014, the Food and Drug Administration (FDA) and Product Quality Research Institute (PQRI) inaugurated their Conference on Evolving Product Quality. The Conference is conceived as an annual forum...
CNS drug delivery: Opioid peptides and the blood-brain barrier
Peptides are key regulators in cellular and intercellular physiological responses and possess enormous promise for the treatment of pathological conditions. Opioid peptide activity within the central nervous system (CNS)...
Evolving importance of biologics and novel delivery systems in the face of microbial resistance
Methods to control infectious diseases in livestock are growing in importance. As the size of the average farm increases-for poultry, dairy and beef cattle, swine, and fish-the risk of rapid spread of infectious diseases...
Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease
Parkinson’s disease is an age-related degenerative disorder of the central nervous system that often impairs the sufferer’s motor skills and speech, as well as other functions. Symptoms can include tremor...
Liposomal Simvastatin Attenuates Neointimal Hyperplasia in Rats
Monocytes, macrophages, and inflammation play a key role in the process of neointimal proliferation and restenosis. The present study evaluated whether systemic and transient depletion of monocytes could be obtained by a...